⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GTBP News
GT Biopharma Inc. Common Stock
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
globenewswire.com
GTBP
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
globenewswire.com
GTBP
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
globenewswire.com
GTBP
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
prnewswire.com
GTBP
IBRX
ERAS
CHRS
NBP
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
globenewswire.com
GTBP
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
prnewswire.com
GTBP
ADCT
STRO
CRNX
TCRX
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
globenewswire.com
ONCY
GTBP